V8 Peptides — Engineered Performance
Research Library
Sermorelin Half-Life: What Published Studies Measured
SermorelinPreclinical

Sermorelin Half-Life: What Published Studies Measured

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does the literature say about sermorelin half-life? There is no single figure. A plasma incubation study found 17 minutes by HPLC for native GHRH(1-44), a review gives about 10–20 minutes for hGRF(1-29) in circulation, and in rats the GH rise after the unmodified 1-29 amide was over in about an hour. Loss runs through N-terminal peptidase cleavage and renal filtration; stability in culture medium has not been published.

Half-life is the most-searched pharmacokinetic term for sermorelin and one of the most misquoted, because the numbers in circulation come from different molecules and different assays. This article separates them, shows what the unmodified peptide does against modified analogs in animals, and turns the stability chemistry into bench handling rules. For laboratory research use only; not for human consumption.

Why half-life is a family of questions

"Sermorelin half-life" sounds like one number. In the literature it is at least four different quantities, measured in different matrices, for different molecules, by different assays. This article lays them out so that a number found in one place is not carried into another where it does not apply. Sermorelin is GHRH (1-29) amide; the product page lists its formula C149H246N44O42S, and the pillar overview covers the biology. Here the focus is on persistence: in plasma, in culture medium, in the lyophilized vial and in the reconstituted solution.

QuantityMatrixMolecule studiedWhat it tells you
Plasma half-life by HPLCHuman plasma incubated in vitroNative GRH(1-44)-NH2Rate of loss of the intact peptide; 17 min in the cited study [1]
Plasma half-life by immunoassaySame incubationSame, with its immunoreactive product63 min, because the 3-44 product still cross-reacts [1]
In vivo half-life of the intact native peptideCirculation after intravenous administration in normal subjects (human study)Native GRH(1-44)-NH26.8 min by HPLC; a degradation-product peak appeared within 1 min [1]
In vivo half-life, review statementCirculationhGRF(1-29)About 10–20 min, attributed to renal ultrafiltration and N-terminal enzymatic degradation [2]
Pharmacodynamic durationGH rise in rats or pigsGRF(1-29)NH2 versus PEGylated analogGH returned to control values about 1 h after the unmodified peptide in rats [3]
Shelf life of the powderSealed vial, cold and dryAny lyophilized peptideNot measured in the cited GHRH literature; a handling matter, see below

The first two rows come from the same experiment and differ by a factor of almost four, which is a good demonstration of why the method matters: the assay that sees only the intact molecule reports a short half-life, and the assay that also sees the inactive degradation product reports a long one.

The enzymology: two clearance routes

The plasma literature points to two causes of loss. The first is enzymatic. When native GRH(1-44)-NH2 was incubated with human plasma, sequencing of the major immunoreactive product identified GRH(3-44)-NH2, which had less than 10-3 of the biological activity of the parent, and the pattern was interpreted as inactivation by a plasma dipeptidylaminopeptidase [1]. The same N-terminal Tyr-Ala sequence is the first two residues of the 29-amino-acid peptide. The second route is physical. A review of GRF PEGylation states that the short plasma half-life of hGRF(1-29), reported as about 10–20 minutes in humans, is caused mostly by renal ultrafiltration and enzymatic degradation at the N terminus [2]. A 3.4 kDa peptide is small enough to be filtered at the glomerulus, which is one reason that the successful stabilization strategies add mass or bind a carrier.

The two routes explain the design logic of every later GHRH analog. Substitutions near the N-terminus protect against the peptidase; conjugation to a large carrier protects against both. The library comparison of CJC-1295 and sermorelin covers the substitution pattern, and the maleimide-albumin chemistry is explained in the CJC-1295 with DAC chemistry guide. The point here is narrower: the half-life of unmodified sermorelin is short because the molecule has no protection against either route.

What stabilization studies reveal about the unmodified peptide

Papers on modified analogs include the unmodified 1-29 amide as a comparator, so they are the best source of direct data on sermorelin-like behavior in animals. Three are worth reading closely.

StudyModificationComparatorReported finding
Jetté et al., 2005 [4]Maleimide derivatives of hGRF(1-29) bioconjugated to serum albuminhGRF(1-29)All conjugates had enhanced in vitro stability against dipeptidylpeptidase-IV; the best (CJC-1295) gave a 4-fold higher GH area under the curve over 2 h in rats and was present in plasma beyond 72 h
D'Antonio et al., 2004 [3]Mono-PEGylated GRF(1-29)NH2 (one 5,000 Da PEG chain on Lys 12 or 21)GRF(1-29)NH2In rats GH returned near control 1 h after the unmodified peptide, while the PEGylated analog gave higher AUC over 0.5–48 h; in pigs a subcutaneous dose raised GH and IGF-I
Esposito et al., 2003 [2]PEG5000 at Lys 12 or Lys 21hGRF(1-29)Monopegylated isomers kept in vitro activity similar to hGRF(1-29) and gave a higher pharmacodynamic response than the unmodified molecule

Two conclusions follow, and one limit. First, the unmodified peptide is bioactive but brief in vivo; its GH response is over within about an hour in the rat model cited. Second, extended persistence came from changing the molecule, not from altering conditions. The limit is that these papers measure pharmacodynamic markers, GH and IGF-I, and for some analogs plasma immunoreactivity, rather than a classical plasma concentration-time profile of sermorelin itself. This article does not report a sermorelin half-life in an animal species because none of the cited abstracts does.

Persistence in culture medium

For a researcher using sermorelin in an assay, the relevant half-life is neither plasma nor in vivo but the stability in the medium and vessel in use. No published value for sermorelin in a named medium was found for this article, and the plasma values above should not be transferred to medium. What the literature does give is the list of mechanisms to rule out. Serum-containing media contain peptidases, and the dipeptidylpeptidase-IV that cleaves the N-terminal pair is the best-characterized candidate [1][4]; serum-free media remove most but not all of that. Peptides at low concentrations also adhere to plastic and glass, and recovery depends on the labware, a point documented for peptides generally [5]. The practical design is to measure it: spike the medium at the working concentration, hold for the planned incubation, and quantify intact peptide by LC-MS at time zero and the end. A drop in intact peptide at fixed concentration over time gives a half-life in that system, with the assay that matches the question, intact molecule or activity.

The first-order relation used to turn two time points into a half-life is a formula, not a result: t1/2 = ln 2 ÷ k, where k = ln(C0 ÷ Ct) ÷ t. It assumes simple exponential decay, which may not hold if adsorption saturates or if an enzyme is depleted. Compare at least three time points to check the fit. The calculator handles the dilution side of the same bench work.

Persistence in the vial: lyophilized and reconstituted

The product is a lyophilized powder with a stated storage condition of refrigeration at 2–8 °C and −20 °C for the long term, protected from heat, moisture and light. The chemistry in the sequence supports that guidance: the methionine at position 27 is oxidation-prone, the Asn-Ser pair at positions 8-9 is a classic deamidation site, and the aspartyl residues can isomerize, as discussed in the structure article notation primer and in general reviews of protein and peptide stability [6][7]. These reactions need water and mobility, and the dry state restricts both. Once reconstituted, the peptide is in solution and the same reactions run faster, with freeze-thaw adding its own stresses [8].

StateDominant riskHandling principle drawn from stability literature
Dry, sealed, coldSlow moisture uptake if the seal failsKeep sealed; avoid opening cold vials in humid air; protect from light
Reconstituted, refrigeratedDeamidation, oxidation, adsorption, microbial growthPrepare only what the experiment needs; label with date; see how long reconstituted peptides last
Frozen aliquotsFreeze-concentration and ice-interface stressSingle-use aliquots; avoid repeated freeze-thaw [8]
Working dilutions at pM–nMSurface lossLow-binding tubes; carrier protein if the assay allows [5]

For the bench steps, how to reconstitute a lyophilized peptide and storing research peptides give the procedure, and what lyophilization is explains why the dry cake is the stable form.

Why a longer-acting analog changes the experiment

When persistence changes, the pharmacology changes in kind. In healthy men sampled overnight, a long-acting GHRH analog that binds albumin preserved the pulsatile pattern of GH secretion while trough GH levels rose markedly, which the authors read as the importance of continuous GHRH stimulation for IGF-I production [9]. That is a human clinical study of another molecule and is cited only to illustrate the conceptual point that persistence reshapes the signal; nothing in it describes sermorelin. For laboratory design the implication is that a short-acting peptide gives a brief, pulse-like exposure, and a long-acting one gives a sustained exposure, so the two cannot be compared on concentration alone. The library article on pulsatile GH-axis design develops the point.

A short checklist before quoting a half-life

  1. Name the molecule. Native 44-residue, 1-29 amide, PEGylated or albumin-bound analog: each has a different value.
  2. Name the matrix. Plasma in vitro, circulation in vivo, culture medium or buffer.
  3. Name the assay. Intact peptide by HPLC or LC-MS differs from immunoreactivity, and both differ from bioactivity.
  4. Name the species and system. Rat, pig and human values are not interchangeable.
  5. Check the source type. Original experiment or a review restating it.

Material identity matters as much: if the lot contains oxidized or truncated species, an HPLC half-life of "the peptide" is a blend of several. How to read a COA, HPLC versus mass spectrometry and sermorelin purity testing describe what to verify first, and the COA library lists published documentation. Related compounds are in the shop.

All material discussed here is supplied for laboratory research use only; not for human consumption, and nothing in this article is a recommendation for any use outside a research setting.

Frequently asked questions

What is the half-life of sermorelin?

No single value applies. A review restating the literature gives about 10–20 minutes for hGRF(1-29) in circulation, and an in vitro plasma study of the native 44-residue peptide found 17 minutes by HPLC and 63 minutes by immunoassay. Culture-medium stability has not been published.

Why is the HPLC half-life shorter than the immunoassay half-life?

The immunoassay also detects the inactive 3-44 product, which stays immunoreactive; HPLC separates it from the intact peptide.

Which enzyme removes the first two residues?

A plasma dipeptidylaminopeptidase, interpreted from the identification of GRH(3-44) as the product; dipeptidylpeptidase-IV is the best-characterized candidate for GHRH-family peptides.

Does renal clearance matter?

A PEGylation review attributes the short plasma half-life mostly to renal ultrafiltration plus N-terminal degradation, which is why adding mass is an effective stabilization route.

How long does the GH response to unmodified GRF(1-29) last in rats?

In one rat study, GH returned to values close to control about 1 hour after administration of the unmodified peptide.

Is there a published stability value for sermorelin in cell-culture medium?

None was found for this article. It should be measured under the assay conditions.

How do I calculate a half-life from two measurements?

Use k = ln(C0 ÷ Ct) ÷ t and t1/2 = ln 2 ÷ k, assuming first-order decay, and verify with three or more time points.

Why does the vial need to stay cold and dry?

The sequence contains residues prone to oxidation, deamidation and isomerization, and these reactions need water; dry, cold storage slows them.

Can half-life data for CJC-1295 be used for sermorelin?

No. CJC-1295 with DAC binds albumin and is present in plasma for days in the cited rat work; sermorelin has no such conjugate.

Related reading: Sermorelin Preclinical Research: Animal Model Map, Sermorelin Research Guide: Question Map and Sources, Sermorelin in 2026: What Recent Research Adds.

References

  1. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-13. doi:10.1172/JCI112679
  2. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003;55(10):1279-91. doi:10.1016/s0169-409x(03)00109-1
  3. D'Antonio M, Louveau I, Esposito P, Bertolino M, Canali S. Pharmacodynamic evaluation of a PEGylated analogue of human growth hormone releasing factor in rats and pigs. Growth Horm IGF Res. 2004;14(3):226-34. doi:10.1016/j.ghir.2003.12.014
  4. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. doi:10.1210/en.2004-1286
  5. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
  6. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
  7. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
  8. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
  9. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.